COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM

Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.